Subtype
Pancreatic Neuroendocrine Neoplasm
CI-CAN-00001357Explore in graph →
Non-malignant36 active trials1 evidence items
- NCIt
- C27031
Loading cancer entity…
Subtype
CI-CAN-00001357Explore in graph →
Clinical trials
175 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01384617 | Trial Assessing Roux-en-Y Anastomosis of the Pancreatic Stump to Prevent Pancreatic Fistula Following Distal Pancreatectomy | completed | N/A | 136 | Wakayama Medical UniversityOTHER | 1 | Jul 21, 2016 | clinicaltrials |
| NCT01204476 | Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma | completed | Phase 1 | 27 | National Cancer Institute (NCI)NIH | 1 | Jul 15, 2016 |
| NCT00049023 | Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors | completed | Phase 1 | 27 | O'Dorisio, M SOTHER | 1 | Jun 21, 2016 | clinicaltrials |
| NCT01155258 | Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors | completed | Phase 1 | 19 | University of Southern CaliforniaOTHER | 1 | Jun 13, 2016 | clinicaltrials |
| NCT00416767 | Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery | completed | Phase 2 | 20 | Federation Francophone de Cancerologie DigestiveOTHER | 0 | May 30, 2016 | clinicaltrials |
| NCT01658436 | BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy. | completed | Phase 2 | 31 | Novartis PharmaceuticalsINDUSTRY | 9 | May 2, 2016 | clinicaltrials |
| NCT02125929 | Comparative Study of Robotic, Laparoscopic and Open Surgery for Enucleation of Benign Pancreatic Neoplasms | completed | N/A | 156 | Peking Union Medical College HospitalOTHER | 1 | Aug 6, 2015 | clinicaltrials |
| NCT02400996 | An Analysis of Presentation and Outcome Following Treatment of Pancreatic Endocrine Neoplasms | completed | — | 40 | Medical College and Hospital KolkataOTHER | 0 | Apr 29, 2015 | clinicaltrials |
| NCT00937079 | Whole Body 111In-exendin-4 Imaging Study in Insulinoma Patients | completed | — | 30 | University Hospital, Basel, SwitzerlandOTHER | 1 | Jan 9, 2015 | clinicaltrials |
| NCT00131911 | Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors | completed | Phase 2 | 93 | National Cancer Institute (NCI)NIH | 1 | Nov 17, 2014 | clinicaltrials |
| NCT01121562 | Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors | completed | Phase 2 | 12 | PfizerINDUSTRY | 1 | Jun 30, 2014 | clinicaltrials |
| NCT00942682 | Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors | completed | Phase 1 | 21 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 29, 2014 | clinicaltrials |
| NCT00602082 | Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors | completed | Phase 2 | 84 | Cambridge University Hospitals NHS Foundation TrustOTHER | 1 | Aug 7, 2013 | clinicaltrials |
| NCT00027638 | Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors | completed | Phase 2 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 18, 2013 | clinicaltrials |
| NCT00075439 | Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors | completed | Phase 2 | 90 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00363051 | Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy | completed | Phase 2 | 160 | Novartis PharmaceuticalsINDUSTRY | 11 | May 10, 2013 | clinicaltrials |
| NCT00006368 | Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer | completed | Phase 1 | 60 | Novartis PharmaceuticalsINDUSTRY | 1 | May 1, 2013 | clinicaltrials |
| NCT00004074 | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu | completed | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00017199 | PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors | completed | Phase 2 | — | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jan 31, 2013 | clinicaltrials |
| NCT00434109 | Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization | completed | Phase 2 | 39 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 14, 2012 | clinicaltrials |
| NCT00019786 | Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases | completed | Phase 2 | 67 | National Institutes of Health Clinical Center (CC)NIH | 1 | Mar 23, 2012 | clinicaltrials |
| NCT00005910 | Laparoscopy to Remove Pancreatic Tumors (Insulinomas) | completed | N/A | 23 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH | 1 | Mar 4, 2008 | clinicaltrials |
Data updated 23 days agoSource updated Jul 21, 2016source: clinicaltrials